Patents by Inventor Jane Spetzler
Jane Spetzler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140296131Abstract: The invention relates to truncated GLP-1 analogues, in particular a GLP-1 analogue which is a modified GLP-1(7-35) (SEQ ID No 1) having: i) a total of 2, 3, 4, 5 6, 7, 8, or 9 amino acid substitutions as compared to GLP-1(7-35), including a) a Glu residue at a position equivalent to position 22 of GLP-1(7-35), and b) an Arg residue at a position equivalent to position 26 of GLP-1(7-35); as well as derivatives thereof, and therapeutic uses and compositions. These analogues and derivatives are highly potent, have a good binding affinity to the GLP-1 receptor, also to the extracellular domain of the GLP-1 receptor, which is of potential relevance achieving long-acting, stable GLP-1 compounds with a potential for once weekly administration.Type: ApplicationFiled: June 9, 2014Publication date: October 2, 2014Applicant: NOVO NORDISK A/SInventors: Jane Spetzler, Lauge Schaeffer, Jesper Lau, Janos T. Kodra, Kjeld Madsen, Patrick W. Garibay, Jacob Kofoed, Steffen Reedtz-Runge, Henning Thoegersen, Ingrid Pettersson
-
Patent number: 8815802Abstract: The invention relates to a GLP-1 analog which comprises a histidine (H) residue at a position corresponding to position 31 of GLP-1(7-37) (SEQ ID NO: 1), a glutamine (Q) residue at a position corresponding to position 34 of GLP-1 (7-37) (SEQ ID NO: 1), and a maximum of ten amino acid modifications as compared to GLP-1 (7-37) (SEQ ID NO: 1); wherein the H residue is designated H31, and the Q residue is designated Q34; or a pharmaceutically acceptable salt, amide, or ester thereof. The invention also relates to derivatives thereof, as well as the pharmaceutical use of these analogs and derivatives, for example in the treatment and/or prevention of all forms of diabetes and related diseases. The invention furthermore relates to corresponding novel side chain intermediates. The derivatives are suitable for oral administration.Type: GrantFiled: December 16, 2010Date of Patent: August 26, 2014Assignee: Novo Nordisk A/SInventors: Christoph Kalthoff, Jesper Lau, Jane Spetzler, Patrick William Garibay, Jacob Kofoed, Lars Linderoth
-
Publication number: 20140228285Abstract: The present invention regards an insulin derivative comprising at least 2 albumin binding moieties, wherein said albumin binding moieties comprise fatty diacid substitutions and a method for preparing such an insulin derivative by acylation and/or reductive alkylation. The present invention also concern a pharmaceutical comprising such an insulin derivative.Type: ApplicationFiled: June 14, 2012Publication date: August 14, 2014Applicant: NOVO NORDISK A/SInventors: Thomas Hoeg-Jensen, Peter Madsen, Jane Spetzler, Tina Moeller Tagmose
-
Publication number: 20140179899Abstract: The invention relates to a derivative of a GLP-1 analogue, which analogue comprises a first K residue at a position corresponding to position 37 of GLP-1(7-37) (SEQ ID NO: 1), a second K residue at a position corresponding to position 26 of GLP-1(7-37), and a maximum of ten amino acid modifications as compared to GLP-1(7-37), wherein the first K residue is designated K37, and the second K residue is designated K26, which derivative comprises two albumin binding moieties attached to K26 and K37, respectively, wherein the albumin binding moiety comprises a protracting moiety selected from: Chem. 1, Chem. 2, Chem. 3 or Chem. 4; or a pharmaceutically acceptable salt, amide, or ester thereof.Type: ApplicationFiled: December 10, 2013Publication date: June 26, 2014Applicant: NOVO NORDISK A/SInventors: Patrick William Garibay, Jane Spetzler, Janos Tibor Kodra, Lars Linderoth, Jesper Lau, Per Sauerberg
-
Publication number: 20140088005Abstract: The invention relates to a derivative of a GLP-1 analogue, which analogue comprises a first K residue at a position corresponding to position 27 of GLP-1(7-37) (SEQ ID NO: 1); a second K residue at a position corresponding to position T of GLP-1(7-37), where T is an integer in the range of 7-37 except 18 and 27; and a maximum of ten amino acid changes as compared to GLP-1(7-37); wherein the first K residue is designated K27, and the second K residue is designated KT; which derivative comprises two albumin binding moieties attached to K27 and KT, respectively, via a linker, wherein the albumin binding moiety comprises a protracting moiety selected from HOOC—(CH2)x—CO— and HOOC—C6H4-0-(CH2)y—CO—; in which x is an integer in the range of 6-16, and y is an integer in the range of 3-17; wherein the linker comprises an element of the formula —NH—(CH2)2—(O—(CH2)2)k—O—(CH2)n—CO—, wherein k is an integer in the range of 1-5, and n is an integer in the range of 1-5; or a pharmaceutically acceptable salt, amide, or esteType: ApplicationFiled: April 12, 2012Publication date: March 27, 2014Applicant: NOVO NORDISK A/SInventors: Birgit Wieczorek, Jane Spetzler, Thomas Kruse, Lars Linderoth, Jacob Kofoed
-
Publication number: 20140011732Abstract: The invention relates to protracted peptide derivatives such as Glucagon-Like Peptide-1 (GLP-1), exendin-4, and analogues thereof, as well as therapeutic uses thereof. The peptide derivative of the invention comprises a peptide wherein at least one amino acid residue is derivatized with A-B—C—, or A-B—C-D-. These compounds are useful in the treatment or prevention of diabetes type 2 and related diseases. The compounds are potent, have a low ratio of binding affinity to the GLP-1 receptor in the presence of high/low albumin concentrations, have long half-lives, and have a high affinity of binding to albumin, all of which is of potential relevance for the overall aim of achieving long-acting, stable and active GLP-1 derivatives with a potential for once weekly administration.Type: ApplicationFiled: June 28, 2013Publication date: January 9, 2014Applicant: NOVO NORDISK A/SInventors: Jane Spetzler, Lauge Schaeffer, Jesper Lau, Thomas Kruse, Patrick William Garibay, Soeren Oestergaard, Steffen Reedtz-Runge, Henning Thoegersen
-
Publication number: 20130288960Abstract: The invention relates to a derivative of a GLP-1 analogue, which analogue comprises a first K residue at a position corresponding to position 18 of GLP-1 (7-37) (SEQ ID NO: 1), a second K residue at another position, and a maximum of twelve amino acid changes as compared to GLP-1 (7-37); which derivative comprises two protracting moieties attached to said first and second K residue, respectively, via a linker, wherein the protracting moiety is selected from Chem. 1, Chem. 2, and Chem. 3: Chem.: HOOC—(CH2)x—CO—* Chem. 2: HOOC—C6H4-0-(CH2)y—CO—* Chem. 3: R2—C6H4—(CH2)z—CO—*, in which x is an integer in the range of 6-18, y is an integer in the range of 3-17, z is an integer in the range of 1-5, and R2 is a group having a molar mass not higher than 150 Da; and the linker comprises Chem. 4: *—NH—(CH2)2-(0-(CH2)2)k-0-(CH2)n—CO—*. wherein k is an integer in the range of 1-5, and n is an integer in the range of 1-5; or a pharmaceutically acceptable salt, amide, or ester thereof.Type: ApplicationFiled: November 9, 2011Publication date: October 31, 2013Applicant: Novo Nordisk A/SInventors: Alice Ravn Madsen, Birgit Wieczorek, Jacob Kofoed, Jesper Lau, Jane Spetzler, Janos Tibor Kodra, Lars Linderoth, Patrick William Garibay, Per Sauerberg, Thomas Kruse
-
Publication number: 20130053311Abstract: The invention relates to a GLP-1 analogue which comprises a histidine (H) residue at a position corresponding to position 31 of GLP-1 (7-37) (SEQ ID NO: 1), a glutamine (Q) residue at a position corresponding to position 34 of GLP-1 (7-37) (SEQ ID NO: 1), and a maximum of ten amino acid modifications as compared to GLP-1 (7-37) (SEQ ID NO: 1); wherein the H residue is designated H31, and the Q residue is designated Q34; or a pharmaceutically acceptable salt, amide, or ester thereof. The invention also relates to derivatives thereof, as well as the pharmaceutical use of these analogues and derivatives, for example in the treatment and/or prevention of all forms of diabetes and related diseases. The invention furthermore relates to corresponding novel side chain intermediates. The derivatives are suitable for oral administration.Type: ApplicationFiled: December 16, 2010Publication date: February 28, 2013Applicant: Novo Nordisk A/SInventors: Christoph Kalthoff, Jesper Lau, Jane Spetzler, Patrick William Garibay, Jacob Kofoed, Lars Linderoth
-
Publication number: 20130012432Abstract: The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.Type: ApplicationFiled: February 28, 2011Publication date: January 10, 2013Applicant: Novo Nordisk A/SInventors: Kilian Waldemar Conde-Frieboes, Jane Spetzler, Ulrich Sensfuss, Birgitte Schjellerup Wulff, Henning Thoegersen, Jens Christian Norrild
-
Publication number: 20120283170Abstract: This invention provides new therapeutic peptides, i.e. new protracted Exendin-4 compounds, pharmaceutical compositions and the use of such.Type: ApplicationFiled: May 1, 2012Publication date: November 8, 2012Applicant: Novo Nordisk A/SInventors: Jesper Lau, Thomas Kruse Hansen, Leif Christensen, Kjeld Madsen, Lauge Schaeffer, Jane Spetzler
-
Publication number: 20110275559Abstract: The present invention relates to a PYY or PP peptide derivative or analogue thereof derivatised with one or more serum albumin binding side chains comprising a dis-tal tetrazole or carboxylic acid group. Moreover, the invention relates to compositions hereof and methods of treatment of conditions responsive to Y receptor modulation.Type: ApplicationFiled: May 18, 2009Publication date: November 10, 2011Applicant: Novo Nordisk A/SInventors: Søren Østergaard, Sanne Møller Knudsen, Jane Spetzler, Rasmus Jørgensen, Jacob Kofoed
-
Publication number: 20110166321Abstract: The invention relates to a derivative of a GLP-1 analogue, which analogue comprises a first K residue at a position corresponding to position 37 of GLP-1(7-37) (SEQ ID NO: 1), a second K residue at a position corresponding to position 26 of GLP-1(7-37), and a maximum of ten amino acid modifications as compared to GLP-1(7-37), wherein the first K residue is designated K37, and the second K residue is designated K26, which derivative comprises two albumin binding moieties attached to K26 and K37, respectively, wherein the albumin binding moiety comprises a protracting moiety selected from: HOOC—(CH2)x—CO—*??Chem. 1: HOOC—C6H4—O—(CH2)y—CO—*??Chem. 2: R1—C6H4—(CH2)z—CO—*??Chem. 3: HOOC—C4SH2—(CH2)w—CO—*??Chem. 4: in which x is an integer in the range of 6-18, y is an integer in the range of 3-17, z is an integer in the range of 1-5, R1 is a group having a molar mass not higher than 150 Da, and w is an integer in the range of 6-18; with the proviso that when the protracting moiety is Chem.Type: ApplicationFiled: December 16, 2010Publication date: July 7, 2011Applicant: NOVO NORDISK A/SInventors: PATRICK WILLIAM GARIBAY, JANE SPETZLER, JÁNOS TIBOR KODRA, LARS LINDEROTH, JESPER LAU, PER SAUERBERG
-
Publication number: 20110124556Abstract: Peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, certain of the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonists may also be developed as therapeutics.Type: ApplicationFiled: April 20, 2010Publication date: May 26, 2011Applicants: NOVO NORDISK A/S, ANTYRA INC.Inventors: RENUKA PILLUTLA, RENEE BRISSETTE, ARTHUR J. BLUME, LAUGE SCHAFFER, JAKOB BRANDT, NEIL I. GOLDSTEIN, JANE SPETZLER, SOREN OSTERGAARD, PER HERTZ HANSEN
-
Publication number: 20110082079Abstract: The invention relates to protracted Glucagon-Like Peptide-1 (GLP-1) derivatives and therapeutic uses thereof. The GLP-1 derivative of the invention comprises a modified GLP-1(7-37) sequence having a total of 2-12 amino acid modifications, including Glu22 and Arg26, and being derivatised with an albumin binding residue or pegylated in position 18, 20, 23, 30, 31, 34, 36, 37, or 39. These compounds are useful in the treatment or prevention of diabetes type 2 and related diseases. The compounds are potent, stable, have long half-lives, a high affinity of binding to albumin, and/or a high affinity of binding to the extracellular domain of the GLP-1 receptor (GLP-1R), all of which is of potential relevance for the overall aim of achieving long-acting, stable and active GLP-1 derivatives with a potential for once weekly administration.Type: ApplicationFiled: September 5, 2008Publication date: April 7, 2011Applicant: Novo Nordisk A/SInventors: Jane Spetzler, Lauge Schäffer, Jesper Lau, Thomas Kruse, Patrick William Garibay, Steffen Runge, Henning Thøgersen, Ingrid Petersson
-
Publication number: 20110039779Abstract: The present invention is drawn to new peptides and proteins that bind to human insulin-like growth factor-1 receptor (HIGF-IR), as well as nucleic acids encoding the same, vectors and cells comprising such nucleic acids, pharmaceutical compositions comprising such compounds, and methods of using any thereof, are provided.Type: ApplicationFiled: April 23, 2008Publication date: February 17, 2011Inventors: Soren Ostergaard, Renuta Pillutla, Paul Fletcher, Lauge Schaffer, Stenfeldt Mathiasen, Neil L. Goldstein, Jane Spetzler
-
Publication number: 20100292133Abstract: The invention relates to truncated GLP-1 analogues, in particular a GLP-1 analogue which is a modified GLP-1(7-35) (SEQ ID No 1) having: i) a total of 2, 3, 4, 5 6, 7, 8, or 9 amino acid substitutions as compared to GLP-1(7-35), including a) a Glu residue at a position equivalent to position 22 of GLP-1(7-35), and b) an Arg residue at a position equivalent to position 26 of GLP-1(7-35); as well as derivatives thereof, and therapeutic uses and compositions. These analogues and derivatives are highly potent, have a good binding affinity to the GLP-1 receptor, also to the extracellular domain of the GLP-1 receptor, which is of potential relevance achieving long-acting, stable GLP-1 compounds with a potential for once weekly administration.Type: ApplicationFiled: September 5, 2008Publication date: November 18, 2010Applicant: Novo Nordisk A/SInventors: Jane Spetzler, Lauge Schäffer, Jesper Lau, János Tibor Kodra, Kjeld Madsen, Patrick William Garibay, Jacob Kofoed, Steffen Reedtz-Runge, Henning Thøgersen, Igrid Pettersson
-
Publication number: 20100261637Abstract: The invention relates to protracted peptide derivatives such as Glucagon-Like Peptide-1 (GLP-1), exendin-4, and analogues thereof, as well as therapeutic uses thereof. The peptide derivative of the invention comprises a peptide wherein at least one amino acid residue is derivatized with A-B-C-, or A-B-C-D-. These compounds are useful in the treatment or prevention of diabetes type 2 and related diseases. The compounds are potent, have a low ratio of binding affinity to the GLP-1 receptor in the presence of high/low albumin concentrations, have long half-lives, and have a high affinity of binding to albumin, all of which is of potential relevance for the overall aim of achieving long-acting, stable and active GLP-1 derivatives with a potential for once weekly administration.Type: ApplicationFiled: September 5, 2008Publication date: October 14, 2010Applicant: Novo nordisk A/SInventors: Jane Spetzler, Lauge Schäffer, Jesper Lau, Thomas Kruse, Patrick William Garibay, Søren Østergaard, Steffen Reedtz-Runge, Henning Thøgersen
-
Publication number: 20100016237Abstract: The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.Type: ApplicationFiled: January 17, 2008Publication date: January 21, 2010Applicant: Novo Nordisk A/SInventors: Ulrich Sensfuss, Kilian Waldemar Conde-Frieboes, Jane Spetzler
-
Publication number: 20090318353Abstract: This invention provides new therapeutic peptides, i.e. new protracted Exendin-4 compounds, pharmaceutical compositions and the use of such.Type: ApplicationFiled: August 24, 2007Publication date: December 24, 2009Applicant: Novo Nordisk A/SInventors: Jesper Lau, Thomas Kruse Hansen, Leif Christensen, Kjeld Madsen, Lauge Schäffer, Jane Spetzler
-
Publication number: 20090203581Abstract: The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.Type: ApplicationFiled: July 7, 2006Publication date: August 13, 2009Applicant: Novo Nordisk A/SInventors: Ulrich Sensfuss, Leif Christensen, Jane Spetzler, Kilian Waldemar Conde Frieboes, Henning Thogersen